Abstract Neurons are postmitotic. Once lost because of injury or degeneration, they do not regenerate in most regions of the mammalian central nervous system. Recent advancements nevertheless clearly reveal that new neurons can be reprogrammed from non-neuronal cells, especially glial cells, in the adult mammalian brain and spinal cord. Here, we give a brief overview concerning cell fate reprogramming in vivo and then focus on the underlying molecular and cellular mechanisms. Specifically, we critically review the cellular sources and the reprogramming factors for in vivo neuronal conversion. Influences of environmental cues and the challenges ahead are also discussed. The ability of inducing new neurons from an abundant and broadly distributed non-neuronal cell source brings new perspectives regarding regeneration-based therapies for traumatic brain and spinal cord injuries and degenerative diseases.
Introduction
After development, neurons in mammalian brain and spinal cord largely lose their ability to regenerate after traumatic injuries or neurodegeneration, with the exception of two brain regions: the subventricular zone (SVZ) of the lateral ventricle and the subgranular zone (SGZ) of the dentate gyrus (Bond et al. 2015; Kriegstein and Alvarez-Buylla 2009) . The newly born neurons in these regions have a very restricted distribution and function in the adult brain and are therefore insufficient to repair most of the disrupted neural circuits under pathological conditions.
Cell transplantation has become an attractive therapeutic strategy for neural injuries or degeneration. Multiple cell types, including induced pluripotent stem cells (iPSCs) and iPSC-derived neural stem cells (NSCs) or neurons, have been examined for their ability to improve neural function after injury (Okano and Yamanaka 2014) . In models of spinalcord and brain injuries, iPSC-derived NSCs have shown promise (Matsui et al. 2014; Nishimura et al. 2013) . For Parkinson's disease, dopaminergic neurons from human embryonic stem cells (ESCs) or iPSCs are emerging as a therapeutic approach (Barker et al. 2015; Bjorklund and Kordower 2013) . However, despite significant progress in the field, cell transplantation still faces several major hurdles, including tumorigenesis (Okano and Yamanaka 2014) , immunorejection, and uncertain long-term survival and integration (Nishimura et al. 2013) .
In vivo cell fate reprogramming has emerged as a new way of understanding plasticity and as a potential therapeutic approach for treating neural injuries and neurological diseases. We will review recent advancements in this field, with a focus on neuronal reprogramming in the mammalian brain and spinal cord. We also recommend previous reviews covering this topic (Arlotta and Berninger 2014; Chen et al. 2015; Heinrich et al. 2015; Li and Chen 2016; Peron and Berninger 2015; Smith et al. 2016a, b; Smith and Zhang 2015; Torper and Gotz 2017) .
Overview of reprogramming in vivo
The pioneering study of Buffo et al. (2005) suggested that injury-induced reactive cells could be engineered in vivo toward a neuronal fate. Looking at mouse brain after a stabwound injury, they showed that ectopic expression of a dominant negative form of Olig2 resulted in the transient formation of doublecortin-positive (DCX+) immature neurons in the parenchyma (Buffo et al. 2005) .
Through a series of in vivo screens and genetic lineage mappings, Niu et al. (2013) revealed that the ectopic expression of Sox2 alone is sufficient to reprogram mouse striatal astrocytes into ASCL1+ neural progenitors. These induced progenitors can further expand and differentiate into neurons with the electrophysiological properties of mature neurons (Niu et al. , 2013 . The Sox2-mediated in vivo reprogramming of glial cells into neurons can be similarly accomplished in the adult mouse spinal cord with injury (Su et al. 2014a) . Further genetic studies have demonstrated that Sox2-dependent in vivo reprogramming is regulated by a series of key factors, including Ascl1, Nr2e1, p53, and p21 (Islam et al. 2015; Niu et al. 2015; Wang et al. 2016) .
Brain glial cells can also be directly reprogrammed into neurons without passing through a progenitor state. Direct neuronal reprogramming can be accomplished through the ectopic expression of a combination of neurogenic transcription factors or even a single factor. For example, Torper et al. (2013) showed that Ascl1, Brn2, and Myt1l in combination can convert striatal astrocytes into RBFOX3+ neurons. Interestingly, Guo et al. (2014) demonstrated that Neurod1 alone is sufficient to convert cortical astrocytes and NG2 glia into glutamatergic and GABAergic neurons. Non-neuronal cells in the adult brain can also be induced to become neurons by the ectopic expression of Neurog2 as shown by Grande et al. (2013) .
Not only can the fate of glial cells be reprogrammed, early postmitotic neurons can also be induced to switch their subtypes. In 2013, De la Rossa et al. showed that the ectopic Fezf2 treatment of mouse layer IV spiny neurons during the first postnatal week changed their identity into layer VB output neurons (De la Rossa et al. 2013) . At the same time, Rouaux and Arlotta (2013) reported that Fezf2 reprogramed early postnatal callosal projection neurons of layer II/III into layer-V/VI corticofugal projection neurons.
Together, these early studies demonstrated that cell fates in the early postnatal or even adult mammalian brain or spinal cord can be reprogrammed. Such feats of in vivo cell fate reprogramming are further supported by a plethora of subsequent studies. We will review the underlying molecular and cellular processes with a focus on recent research progresses (Fig. 1) .
Cells of origin for reprogramming
Multiple cell types within the nervous system have been shown to be reprogrammable in vivo. These cells, including astrocytes, NG2 glia, and early postmitotic neurons, are all derived from NSCs during neural development. Some proliferative neural-progenitor-like cells, which normally give rise to glial cells, can also be redirected to become neurons in the adult central nervous system (CNS). The neural origin of these cells may lower the epigenetic barrier to neuronal reprogramming.
Proliferative cells
Proliferation and multilineage differentiation are key features of NSCs in the neural epithelium during development and in the adult neurogenic niches (Kriegstein and Alvarez-Buylla 2009) . Proliferative cells can also be identified in the parenchyma of the adult brain and spinal cord, especially after traumatic injuries or under neural degeneration (Smith et al. 2016b ). Nonetheless, their fates are invariably restricted to glial cells in vivo, although they show neuronal differentiation under in vitro culture conditions.
In vivo proliferative cells can be specifically targeted through Moloney murine leukemia virus-derived retroviral vectors, which require active cell division for viral transduction. These proliferative cells can be induced to generate neurons under certain conditions (Buffo et al. 2005; Guo et al. 2014; Kronenberg et al. 2010; Ohori et al. 2006) . For example, retrovirus infection was able to label a population of neural progenitors expressing OLIG2, NKX2.2, and NG2 in the adult rat spinal cord (Ohori et al. 2006) . Administration of FGF2 and EGF induced neuronal differentiation of these progenitors. Importantly, ectopic expression of Neurog2 through retroviral vectors enhanced neuronal differentiation and maturation, whereas ectopic Ascl1 (also known as Mash1) promoted the generation of oligodendrocytes under the same conditions (Ohori et al. 2006) .
In the adult mouse brain cortex, stab-wound injury or stroke resulted in the proliferation of OLIG2+ glia, which normally give rise to astrocytes (Buffo et al. 2005; Kronenberg et al. 2010) . Retrovirus-mediated expression of Pax6 or a mutant form of Olig2 in these proliferating cells leads to an induction of immature neurons surrounding the injury sites (Buffo et al. 2005; Kronenberg et al. 2010) . Retrovirus can similarly label a subset of cells in the adult rat brain expressing GFAP, NG2, nestin, and OLIG2, which are known markers for neural progenitors (Grande et al. 2013) . These cells are proliferative and can be induced by the ectopic expression of Neurog2 to generate neurons in both the rodent cortex and striatum (Gascon et al. 2016; Grande et al. 2013) . Unexpectedly, after controlled cortical injury, proliferative glial cells have also been reprogrammed in situ to become pluripotent stem cells capable of neural differentiation and tumorigenesis (Gao et al. 2016) .
Recent studies have shown that NSCs located in the SVZ respond to injury, migrate to lesion sites, and differentiate into astrocytes (Benner et al. 2013; Faiz et al. 2015) . These SVZderived glial cells are amenable to reprogramming in vivo (Benner et al. 2013) . Such results raise questions concerning the exact cell of origin for reprogramming strategies targeting proliferative cells, as they show some features of neural progenitors (Buffo et al. 2005; Grande et al. 2013; Ohori et al. 2006) . Lineage-mapping approaches that focus on region and cell type will be essential to determine whether the reprogrammed cells originate from migratory endogenous NSCs or local reactive glial cells.
Astrocytes
Astrocytes are the first clearly defined non-neuronal cell type capable of being reprogrammed in the adult mouse brain (Niu et al. 2013; Torper et al. 2013) . They are also the most abundant and ubiquitously distributed glial cells in the adult CNS. The majority of astrocytes are generated through the local proliferation of previously differentiated astrocytes during the early postnatal stage (Ge et al. 2012) . Under physiological conditions in rodents, astrocyte proliferation largely stops after one month of age (Ge et al. 2012; Tsai et al. 2012) . However, in response to damage or neurodegeneration, adult astrocytes become reactive and change morphology, gene expression, and proliferation status (Robel et al. 2011; Sofroniew and Vinters 2010) . Some of these reactive astrocytes form a glial scar that surrounds the injury site and plays a complex role during various phases of post-injury recovery (Robel et al. 2011; Sofroniew 2009; Sofroniew and Vinters 2010) . When isolated and cultured in vitro, reactive astrocytes can form neurospheres and gain the potential for multilineage differentiation; however, they remain astrocytes and do not generate any neurons in vivo (Buffo et al. 2005; Gotz et al. 2015) .
Astrocytes can be specifically targeted in vivo with celltype-restricted promoters in the viral vectors and genetic lineage-tracing mouse lines (Guo et al. 2014; Liu et al. 2015; Niu et al. 2013; Su et al. 2014a; Torper et al. 2013; Wang et al. 2016) . A genomic sequence containing promoter and enhancer elements of human GFAP (hGFAP) gene has frequently been used to drive astrocyte-restricted gene expression (Lee et al. 2008; Zhuo et al. 2001 ). This hGFAP genomic sequence, also called hGFAP promoter, can be incorporated into either retrovirus, lentivirus, or adeno-associated virus (AAV) for in vivo gene delivery (Guo et al. 2014; Liu et al. 2015; Niu et al. 2013; Su et al. 2014a ). An added advantage is that hGFAP promoter drives high gene expression in reactive astrocytes, but its activity is then greatly downregulated once cells are reprogrammed into neurons (Niu et al. 2013) .
Lentivirus with hGFAP promoter-driven GFP, when injected into adult mouse brain or spinal cord, is reported to be active and to confer a strong GFP signal in surrounding regions (Niu et al. 2013; Su et al. 2014a) . A majority of the infected GFP+ cells are GFAP-expressing astrocytes (Niu et al. 2013; Su et al. 2014a) . Ectopic expression of Sox2 in these cells robustly induces new neurons Su et al. 2014a; Wang et al. 2016) . Proliferative GFAP+ astrocytes can also be targeted for reprogramming by a retrovirus under the constitutively active CAG promoter or the astrocyte-restricted hGFAP promoter (Guo et al. 2014) . Furthermore, serotype 8 AAV with the hGFAP promoter has been shown to target brain astrocytes efficiently (Liu et al. 2015) .
Genetically modified mouse lines have also been employed conclusively to determine an astrocyte origin for reprogrammed neurons (Liu et al. 2015; Niu et al. 2013; Su et al. 2014a; Torper et al. 2013; Wang et al. 2016) . The GFAPCre line 77.6 has been shown to be specific for astrocytes in the brain and spinal cord (Gregorian et al. 2009 ). Such astrocyte-restricted Cre activity has subsequently been confirmed by using fluorescent proteins as reporters (Niu et al. 2013; Su et al. 2014a; Torper et al. 2013) . Notably, this Cre line also labels a very small percentage of other neural cell types, such as NG2 glia. The injection of lentiviruses that encode the Cre-dependent expression of three transcription factors is sufficient to induce new neurons in the striatum of this Cre line (Torper et al. 2013 ). This mouse line has also been employed in several other in vivo reprogramming studies including the adult mouse brain and spinal cord (Niu et al. 2013; Su et al. 2014a; Wang et al. 2016) .
Tamoxifen-inducible Cre-dependent lineage tracing mouse lines may be superior to constitutively active Cre lines, because the target cells in the inducible lines can be pre-labeled with a fluorescent reporter under physiological conditions, and because their fates can be followed during reprogramming. Cystatin C (Cst3) is enriched in adult astrocytes throughout the brain (Bachoo et al. 2004) . A BAC transgenic mouse line harboring the CreER T2 fusion gene in the Cst3 locus shows tamoxifen-dependent Cre activity restricted to striatal astrocytes (Niu et al. 2013) . When the RosatdTomato reporter is used (Madisen et al. 2010) , astrocyteconverted neurons can be clearly identified by tdTomato expression in whole-cell patch-clamp recordings (Niu et al. 2013) . hGFAP-CreER T2 mice, in which the CreER T2 fusion gene is under the control of a 2.2-kb hGFAP promoter (Ganat et al. 2006) , have been used to verify the astrocyte-restricted expression of AAV-mediated genes (Liu et al. 2015) .
Because NSCs might migrate from SVZ to the injury site and differentiate into astrocytes (Benner et al. 2013; Faiz et al. 2015) , one should be cautious in concluding that induced neurons arose from resident/local astrocytes. An unambiguous conclusion can be drawn by employing additional lineage tracing mouse lines (Niu et al. 2013) . For example, endogenous NSCs and their derivatives from the SVZ and SGZ have been genetically traced in Nes-CreER TM mice (Benner et al. 2013; Kuo et al. 2006; Niu et al. 2013) . Furthermore, although lentivirus or AAV with the hGFAP promoter predominantly expresses genes of interest in astrocytes, a small fraction of endogenous neurons are also targeted by these viral vectors. On the other hand, one reservation that has to be mentioned with regard to retrovirus is that it can induce microglia-neuron fusion, especially under pathological conditions (Ackman et al. 2006 ).
NG2 glia
NG2 glia, also known as oligodendrocyte precursor cells, are ubiquitously distributed throughout the adult CNS and serve as a pool of progenitors to differentiate into oligodendrocytes (Nishiyama et al. 2016 ). In the adult brain, they are the major proliferative glial cells under physiological conditions (Buffo et al. 2008; Kang et al. 2010) . After injury, NG2 glia increase their numbers and become a major component of cells surrounding the lesion site (Lytle and Wrathall 2007; McTigue et al. 2001; Tripathi and McTigue 2007; Zai and Wrathall 2005) . These cells have been shown to give rise to scarforming astrocytes and myelin-producing oligodendrocytes following spinal cord injury (Sellers et al. 2009; Zhu et al. 2008 ). In the adult brain, ectopic expression of one or more transcription factors in NG2 glia can reprogram them into neurons (Guo et al. 2014; Heinrich et al. 2014; Torper et al. 2015) .
A promoter sequence from the NG2 gene has frequently been used in combination with a viral vector to drive gene expression in NG2 glia (Guo et al. 2014; Sellers et al. 2009; Zhu et al. 2008 ). Interestingly, a significant fraction of the cells labeled by a reporter under the NG2 promoter in a retroviral vector were GFAP+ astrocytes surrounding the injury site (Sellers et al. 2009 ). Possibly, either that a high percentage of NG2 glia differentiate into GFAP+ astrocytes or some reactive astrocytes upregulate NG2 expression. To prevent such ambiguity, additional lineage-tracing methods are needed to target NG2 glia when using viral vectors.
Genetically modified mouse lines are ideal for tracing descendants of NG2 glia during the reprogramming process. The tamoxifen-inducible NG2-CreER TM and PDGFRα-CreER are common transgenic mouse lines used to fate-map NG2 glia (Kang et al. 2010; Rivers et al. 2008; Zhu et al. 2011 ). The NG2-CreER TM mouse line has a recombination efficiency of about 30-40% of NG2 glia (Hackett and Lee 2016; Zhu et al. 2011) , whereas the PDGFRα-CreER line has a recombination efficiency of over 90% (Kang et al. 2010) . Similarly, the Sox10-iCreERT2 T2 line could efficiently trace NG2 glia and mature oligodendrocytes (Simon et al. 2012 ) and was employed to reveal an NG2 glia origin for Sox2-mediated direct reprogramming in the adult mouse cerebral cortex following stab-wound injury (Heinrich et al. 2014) . By using the NG2-Cre transgenic mice (Zhu et al. 2008 ) and Credependent AAV vectors for gene expression, a combination of transcription factors was able to reprogram brain NG2 glia into neurons (Torper et al. 2015) .
Although a majority of the genetically traced cells in the above-described mouse lines remained as NG2 glia or differentiated into oligodendrocytes, a small fraction of them transiently expressed GFAP after neural injury (Sellers et al. 2009 ). These GFAP-expressing cells might uniquely contribute to the reprogrammed neurons. Therefore, caution is needed when determining an NG2 glia origin during in vivo reprogramming. As precursors for oligodendrocytes, NG2 glia are critical for replenishing lost myelin-forming oligodendrocytes after injury (Kucharova and Stallcup 2015) . Thus, the reprogramming of NG2 glia into neurons needs to be finely tuned so that a sufficient number of these cells will be kept for neural repair after injury. On the other hand, because these cells can divide and replenish themselves, they may represent a superior cell source for in vivo reprogramming.
Neurons
In the CNS, neurons represent a quintessential example of a permanently post-mitotic and differentiated cell type. They are mainly born during embryonic and early postnatal stages, except for in few regions of the adult brain. Once generated, neurons become permanently post-mitotic and do not change their identity for the lifespan of the organism. However, recent studies suggest that the identity of early postmitotic neurons can be reprogrammed in vivo (De la Rossa et al. 2013; Rouaux and Arlotta 2013) . The acquisition of new identity has been confirmed by molecular, morphological and electrophysiological criteria (De la Rossa et al. 2013; Ye et al. 2015) . These results pave the way for mechanistic studies aimed at extending the period of neuronal reprogramming to the mature brain (Rouaux and Arlotta 2013) .
Genes for reprogramming
Decades of research into neural development have revealed that many genes play critical roles for cell-fate specification and maintenance. These genes, especially transcription factors and microRNAs, are excellent study candidates for reprogramming cell fates in vivo. Here, we will discuss alphabetically some of these critical genes that have been confirmed to be able to induce cell fate changes in vivo, either alone or in combination with other factors.
Ascl1
Achaete-scute family bHLH transcription factor 1 (Ascl1, also known as Mash1) plays a critical role in neuronal commitment and differentiation and in generating olfactory and autonomic neurons (Huang et al. 2014 ). Ectopic Ascl1 is sufficient to promote the neuronal differentiation of ESCs, NSCs, and early postnatal astroglia (Berninger et al. 2007; Chanda et al. 2014; Heinrich et al. 2011) . As a pioneer factor, Ascl1, in combination with Brn2 and Myt1l or with Lmx1a and Nurr1, induces neuronal conversion of both mouse and human fibroblasts in culture (Caiazzo et al. 2011; Torper et al. 2013; Vierbuchen et al. 2010; Wapinski et al. 2013 ). These two combinations of three transcription factors have also been able directly to convert astrocytes or NG2 glia into neurons in the adult mouse striatum, although none of these induced neurons are DARPP32+ striatal medium spiny neurons or TH+ dopaminergic neurons (Torper et al. 2013 (Torper et al. , 2015 . However, when Ascl1 is combined with Neurod1, Lmx1a, and the microRNA miR218, mouse striatal astrocytes are reprogrammed into functional dopaminergic neurons that can ameliorate some behavioral deficits in a mouse model of Parkinson's disease (Rivetti di Val Cervo et al. 2017 ).
Intriguingly, the AAV-mediated ectopic expression of Ascl1 has subsequently been shown to be sufficient for robustly inducing mature neurons from astrocytes in the dorsal midbrain, striatum, and somatosensory cortex of postnatal mice (Liu et al. 2015) . Both GAD1+ GABAergic and VGLUT2+ glutamatergic neurons can be identified under this reprogramming paradigm in vivo (Liu et al. 2015) . These induced neurons exhibit the electrophysiology and synaptic connections of mature neurons. Nonetheless, such neuronal induction has not been observed when Ascl1 expression is mediated through either a lentiviral or retroviral vector in the adult brain and spinal cord (Grande et al. 2013; Heinrich et al. 2014; Jessberger et al. 2008; Niu et al. 2015; Ohori et al. 2006) . Instead, ectopic Ascl1 induces oligodendrocytes from glial progenitors in the spinal cord (Ohori et al. 2006) or from NSCs in the SGZ (Jessberger et al. 2008) . The factor that contributes to this discrepant reprogramming activity of Ascl1 remain unclear, although various viral vectors might induce differential host responses that influence reprogramming. On the other hand, ectopic Ascl1 in combination with a histone deacetylase inhibitor can reprogram retinal Müller glia into inner-retina neurons that form synapses and respond to light (Jorstad et al. 2017 ).
Fezf2
Fez family zinc finger protein 2 (Fezf2) is a transcriptional repressor required for specifying corticospinal motor neurons and some subcerebral projection neurons (Molyneaux et al. 2007) . It also controls the development of dendritic arbors and spines of large pyramidal neurons in layer V. Ectopic expression of Fezf2 can switch early postmitotic callosal-projection neurons and layer IV interneurons into glutamatergic corticofugal projection neurons (De la Rossa et al. 2013; Rouaux and Arlotta 2013) . Interestingly, these reprogrammed excitatory neurons can extrinsically modulate inhibitory input from local interneurons indicating the rewiring of the cortical microcircuit .
Neurod1
Neurod1 (neuronal differentiation 1) is a member of the Neurod family of bHLH transcription factors (Lee et al. 1995) . Deletion of Neurod1 in mice results in severe neuronal deficit in the granule layers of the cerebellum and hippocampus (Miyata et al. 1999; Schwab et al. 2000) . It is also essential for the maturation and survival of adult-born neurons in the hippocampus and olfactory bulb (Gao et al. 2009; Kuwabara et al. 2009 ).
When ectopically expressed through a retroviral vector, Neurod1 efficiently induces DCX+ cells, which quickly became RBFOX3+ mature neurons, in the cortex of adult mice with brain injury or Alzheimer's disease (Guo et al. 2014 ).
Interestingly, Neurod1 reprogrammes cortical astrocytes into glutamatergic neurons and NG2 glia into both glutamatergic and GABAergic neurons (Guo et al. 2014 ). These converted neurons show spontaneous and evoked synaptic responses, indicating their integration into local neural circuits. Such Neurod1-mediated robust neuronal reprogramming of glia may require injury-or degeneration-induced glial reactivation and a higher level of Neurod1 expression, since non-reactive astrocytes only show limited neuronal transdifferentiation with Neurod1 (Brulet et al. 2017 ).
Neurog2
Neurogenin 2 (Neurog2) is another bHLH transcription factor involved in neural specification and neurogenesis by inducing the expression of proneuronal genes and inhibiting the expression of glial genes (Marquardt and Pfaff 2001; Morrison 2001) . As a pioneer factor, Neurog2 in combination with small molecules very efficiently reprogramme human fibroblasts to cholinergic neurons in vitro (Liu et al. 2016 Smith et al. 2016c ). In culture, both mouse astroglia and human glioma cells can be reprogrammed into neurons by Neurog2, either alone or in combination with Sox11 (Heinrich et al. 2010; Su et al. 2014b ). Retroviral expression of Neurog2 in proliferating cells induces neurons in the spinal cord, striatum, and cortex (Gascon et al. 2016; Grande et al. 2013; Ohori et al. 2006) . Such in vivo neuronal inductions are further enhanced by growth factors (Grande et al. 2013; Ohori et al. 2006) or by Bcl2 co-expression and anti-oxidative treatments (Gascon et al. 2016) . These induced neurons are predominantly deep-layer glutamatergic pyramidal neurons in the cortex (Gascon et al. 2016) or GABAergic but DARPP32-negative inhibitory neurons in the striatum (Grande et al. 2013 ).
Olig2
Oligodendrocyte transcription factor 2 (Olig2) belongs to the family of bHLH transcription factors (Lu et al. 2000; Zhou et al. 2000) . It controls the development of oligodendrocytes and certain neuronal subtypes (Mizuguchi et al. 2001; Novitch et al. 2001; Takebayashi et al. 2002; Zhou and Anderson 2002) . It also plays an essential role in transit-amplifying precursors in the adult subependymal zone (Hack et al. 2005 (Hack et al. , 2004 . The expression of Olig2 was broadly upregulated in reactive glial cells after both acute and chronic brain lesions, although no neurons were induced under such conditions (Buffo et al. 2005) . Interestingly, the ectopic expression of a dominant active form of Olig2, whereby the Olig2 repressor domain was replaced by the Herpes simplex VP16 protein (Olig2VP16; Hack et al. 2005 Hack et al. , 2004 Mizuguchi et al. 2001; Novitch et al. 2001) , induced the formation of DCX+ neuroblasts surrounding the lesion sites (Buffo et al. 2005; Kronenberg et al. 2010) . Such results suggest that a normal function of the injury-induced upregulation of Olig2 is to keep the reactive cells in a glial lineage. Nonetheless, only a small fraction of the Olig2VP16-expressing cells become DCX+ cells, indicating that additional factor(s) are needed for more robust induction of neurogenesis.
Sox2
Sox2, a member of the Sox family of transcription factors, plays key roles in many stages of mammalian development, such as the maintenance of ESCs and NSCs (Favaro et al. 2009; Ferri et al. 2004; Graham et al. 2003; Miyagi et al. 2008; Suh et al. 2007) . It is one of the original four Yamanaka factors capable of reprogramming somatic cells into pluripotent stem cells (Takahashi and Yamanaka 2006) . Its expression has been shown to convert mouse and human fibroblasts into NSCs under a special culture condition (Ring et al. 2012) .
Through in vivo screens of mini-pools of genes, which include eight transcription factors (Ascl1, Brn2, Klf4, Myc, Myt1l, Oct4, Sox2, and Zfp521) and four microRNAs (miR9, miR124, miR125, and miR128), Sox2 alone has been identified to be sufficient robustly to induce DCX+ neuroblasts in the adult mouse striatum (Niu et al. 2013 ). Systematic lineage mappings by using genetically modified mice have revealed that local astrocytes are the cell of origin of the induced neuroblasts (Niu et al. 2013) . These induced neuroblasts proliferate and pass through an ASCL1+ progenitor stage before becoming mature neurons . Genetic interactions have further demonstrated that Sox2 directly controls the expression of Nr2e1 (also known as Tlx), an orphan nuclear receptor, and requires Ascl1 and Nr2e1 for in vivo reprogramming (Islam et al. 2015; Niu et al. 2015) .
Sox2 was also sufficient for the neuronal reprogramming of glial cells in the adult mouse spinal cord (Su et al. 2014a) . To understand the reprogramming process, additional in vivo screens were conducted for multiple genes, including Pten, p53, Pax6, Neurog2, Ascl1, Sox11, Nr2e1, Pou5f1, Olig2, Ptf1a, Sox1, Sox3, Brn2, Neurod1, Fgf2, miR-9/9 * , and miR-124. Among these, only the p53-p21 pathway was shown to have a significant impact on the in vivo reprogramming process in the adult mouse spinal cord ). Removal of p53 or p21 greatly enhanced the generation of Sox2-induced neuroblasts. When genes for neurotrophic factors, especially BDNF and Noggin (NOG), were coexpressed, the induced neuroblasts became mature neurons expressing RBFOX3, MAP2, and SYN1 (Su et al. 2014a; Wang et al. 2016) . Interestingly, a majority of the induced neurons were VGLUT2+ excitatory interneurons in the adult spinal cord . This was in sharp contrast to those neurons induced in the adult striatum, the majority of which were CR+ inhibitory interneurons . These results indicate that the regional identity of the glial cells and/or the microenvironments greatly influence the subtypes of the induced neurons.
Unexpectedly, cortical NG2 glia can be directly converted into neurons through the retrovirus-mediated expression of Sox2 (Heinrich et al. 2014 ). This conversion requires stabwound-induced pre-lesion in the cortex and does not require the downregulation of Sox2 expression in the induced neurons. This contrasts with the Sox2-mediated reprogramming of astrocytes in the adult striatum, in which the constitutive expression of Sox2 blocks the robust induction of DCX+ cells and their further maturation into neurons (Niu et al. 2013) . Future experiments are urgently needed if we are to understand the way that Sox2 exerts such diverse effects in different contexts.
Microenvironments on reprogramming
Although in vivo reprogramming is dominantly initiated by the ectopic expression of key transcription factors, the reprogramming process and the final cell types are highly influenced by the microenvironment.
Neural injury and degeneration
Glial cells react to injury or degenerative conditons with changes in morphology, gene expression, and proliferation (Gotz et al. 2015; Robel et al. 2011; Sofroniew 2009; Sofroniew and Vinters 2010) . Such cellular responses may alter the chromatin structure and the epigenetic status that facilitate fate changes during reprogramming. Indeed, studies with a mouse traumatic injury model by inserting a thin knife into the cortical parenchyma (Bardehle et al. 2013; Buffo et al. 2005) have shown that stab-wound injury prior to viral injections is essential for the Sox2-mediated reprogramming of cortical NG2 glia (Heinrich et al. 2014) . Ischemic insults also moderately promote Neurog2-induced neuronal production, survival, and maturation from non-neuronal cells in the adult rat striatum and neocortex (Grande et al. 2013) . The number of Neurod1-induced neurons is significantly higher in mouse cortex of an Alzheimer's disease model than in wild-type mice; such an increase correlates positively in an agedependent manner with the number of disease-induced reactive glial cells (Guo et al. 2014) . In contrast, ectopic Neurod1 rarely induces any neurons from either cultured or resident astrocytes under non-reactive conditions (Brulet et al. 2017 ).
Regional identity
Like neurons, glial cells are heterogeneous and show different morphology, gene expression, and function in different parts of the brain and spinal cord (Bachoo et al. 2004; Molofsky et al. 2014; Tsai et al. 2012 ). Regional differences are also shown in the extracellular matrix, cytokines, neurotransmitters, and morphogens. Studies have revealed that such regional differences influence the in vivo reprogramming process. For instance, in the adult striatum, a majority of the Sox2-induced neurons were CR+ inhibitory neurons, whereas those in the adult spinal cord are VGLUT2+ excitatory neurons, although all of these reprogrammed cells pass through an ASCL1+ progenitor stage Wang et al. 2016) . The striatum and neocortex also demonstrate a differential response to ectopic Neurog2 expression and growth factor treatments (Grande et al. 2013) . Neurog2-induced neurons in the striatum exhibit properties of striatal projection neurons, whereas those in the neocortex are largely glutamatergic (Gascon et al. 2016; Grande et al. 2013 ).
Growth factors
Fibroblast growth factor 2 (FGF2), also known as bFGF or FGF-β, is involved in multiple biological process. Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Both of them are essential growth factors for culturing isolated neural progenitor cells (Kuhn et al. 1997) . The in vivo delivery of FGF2 and EGF proteins significantly increases the number of Neurog2-induced neurons from proliferative cells in the adult rat brain (Grande et al. 2013 ).
Brain-derived neurotrophic factor (BDNF), a neurotrophic factor not expressed in the striatum, promotes neuronal differentiation, survival, and maturation (Altar et al. 1997; Huang and Reichardt 2001) . NOG, a bone morphogenetic protein antagonist, promotes adult neurogenesis in the SVZ (Lim et al. 2000) . Virus-mediated co-expression of BDNF and NOG greatly promote long-term survival and maturation of Sox2-induced neurons in the adult striatum and spinal cord, although their expression alone has no effect on cell reprogramming (Niu et al. , 2013 Wang et al. 2016) . Additionally, GDNF and FGF2 also show mild enhancement of the maturation of reprogrammed neurons in the adult mouse spinal cord ).
Small molecules
Valproic acid (VPA), a histone deacetylase inhibitor and common anti-convulsant, was shown to induce BDNF expression and to promote neuronal differentiation (Fukumoto et al. 2001; Hall et al. 2002; Hao et al. 2004; Hsieh et al. 2004 ). Administration of VPA through either intraperitoneal injections or in drinking water significantly enhanced the generation of mature neurons for Sox2-mediated reprogramming in the adult brain and spinal cord (Niu et al. , 2013 Su et al. 2014a) . Intravitreal injection of trichostatin-A (TSA), another histone deacetylase inhibitor, was required for the Ascl1-mediated reprogramming of Müller glia to inner retinal neurons (Jorstad et al. 2017) . The Neurog2-dependent reprogramming process was also greatly enhanced by small-molecule treatments (Gascon et al. 2016) . Oral gavage of calcitriol (a ligand for vitamin D receptor) or α-tocotrienol (a vitamin E analog) greatly improved the reprogramming efficiency and maturation of Neurog2-induced neurons in the adult mouse cortex (Gascon et al. 2016) .
Challenges for reprogramming in vivo
The ability to engineer cell fates in living animals brings new perspectives regarding cell identity and regeneration-based therapies for neural injury and degeneration. A cell fate requires active maintenance such that it can be completely changed by altering its genetic and epigenetic compositions, even in the adult animal. Such fate changes might replace the much-needed neurons lost because of traumatic injury or neurodegenerative diseases. Since the newly induced neurons are derived from a patient's own cells, they are immunecompatible with the host and avoid cell rejections that are frequently associated with transplantation-based approaches. To realize the full potential of reprogramming in vivo, significant challenges need to be overcome, although substantial progress has been made in recent years.
First, a large number of induced neurons may be required for neural repair associated with traumatic injury or neurodegeneration. For the direct neuronal conversion of glial cells, such as those initiated by the ectopic expression of Neurod1, Neurog2, Olig2, or Ascl1, the final number of induced neurons is determined by the number of virus-transduced cells, conversion efficiency, and cell survival. Although conversion efficiency is quite high (Guo et al. 2014) , the number of virus-transduced and survived cells is very limited. Such limitation may be partially overcome by simultaneous treatments with growth factors and/or small chemicals, such as FGF2, EGF, calcitriol, or α-tocotrienol (Gascon et al. 2016; Grande et al. 2013) .
The number of induced neurons can also be increased if the reprogramming passes through an expandable precursor state, such as that mediated by the ectopic expression of Sox2 (Niu et al. , 2013 Wang et al. 2016) . ASCL1+ progenitors and DCX+ neuroblasts are intermediate precursors for the Sox2-dependent reprogramming of resident glial cells. These precursors are proliferative and can generate a large number of induced neurons when neurotrophic factors are also supplied. Interestingly, neuronal production can be further increased by the removal of the p53-p21 pathway . Although the permanent removal of tumor suppressors may not be ideal for therapy, transient suppression may be accomplished either through shRNA-mediated downregulation or by the application of small molecule inhibitors.
Second, the induced neurons need to become mature and survive in the long term. The environment of the adult brain and spinal cord is not conducive to young neurons because the expression of many neurotrophic factors diminishes with age. This may contribute to the poor survival and maturation of many of these glia-converted neurons (Gascon et al. 2016; Guo et al. 2014; Niu et al. 2013; Wang et al. 2016) . Engineering the microenvironment has shown promise. For example, the co-expression of BDNF and NOG greatly increases the number of surviving mature neurons in both the adult brain and spinal cord (Niu et al. , 2013 Wang et al. 2016) . Treatments with small molecules, such as VPA, calcitriol, or α-tocotrienol, also enhances neuronal survival and maturation (Gascon et al. 2016; Niu et al. 2015 Niu et al. , 2013 Su et al. 2014a ). Co-expression of BCL2 improves neuronal reprogramming and survival through an apoptosisindependent mechanism (Gascon et al. 2016) .
Third, an appropriate neuronal subtype and network integration are prerequisites for the beneficial functions of the induced neurons. Neuronal subtypes may be differentially lost after injury and neurodegeneration. For example, neural injury and Alzheimer's disease affect a variety of neurons, but Parkinson's disease (PD) uniquely attacks dopaminergic neurons. The current reprogramming strategies are able to generate excitatory glutamatergic and inhibitory GABAergic neurons in both the adult brain and spinal cord (Gascon et al. 2016; Grande et al. 2013; Guo et al. 2014; Liu et al. 2015; Niu et al. 2015 Niu et al. , 2013 Su et al. 2014a; Torper et al. 2015; Wang et al. 2016 ). Whole-cell patch-clamp recordings of the induced neurons have revealed electrophysiological properties for mature neurons, including action potentials and synaptic connections. However, whether these neurons have appropriately integrated into a functional network for behavior remains unclear. Encouragingly, a recent study has shown that a combination of factors, including Ascl1, Neurod1, Lmx1a, and miR128, induces glial conversion to dopaminergic neurons (Rivetti di Val Cervo et al. 2017) . Such in vivo programming ameliorates certain behavioral deficits in a mouse model of PD.
Fourth, the underlying molecular and cellular mechanisms are coming to light. In cultured cells, deep sequencing-based genome-wide systematic analyses have shown that key reprogramming factors, such as Ascl1 and Neurog2, act as pioneer factors to initiate and coordinate the genetic and epigenetic events that eventually lead to fate switching (Smith et al. 2016c; Wapinski et al. 2013) . Pathways involved in oxidative stress and ferroptosis have also been revealed as key metabolic checkpoints during the glia-to-neuron conversion (Gascon et al. 2016) . A candidate approach has demonstrated Ascl1, Nr2e1, and the p53-p21 pathway to be key regulators of Sox2-mediated reprogramming in the adult brain and spinal cord (Islam et al. 2015; Niu et al. 2015; Wang et al. 2016) . These research gains notwithstanding, our mechanistic knowledge of the in vivo reprogramming process is still rudimentary; hurdles remain such as cellular heterogeneity, the asynchronous nature of the reprogramming process, and the intricate in vivo environment. Further research may be greatly facilitated by recent developments in single-cell-based deep sequencing and advanced bioinformatics (Shin et al. 2015) .
Lastly, safe and efficient methods are essential for clinical applications. The various gene-delivery methods employed for proof-of-principle studies carry dangers. Retrovirus and lentivirus have a larger cDNA-insert packaging capacity and can efficiently transduce a variety of cell types and mediate long-term stable gene expression (Lukashev and Zamyatnin 2016) . Nonetheless, their genome integration ability might result in the mutagenesis of genes critical for normal cell function or tumorigenesis. The non-integrating AAV vectors are a preferred method for gene therapy (Lukashev and Zamyatnin 2016) . Interestingly, the AAV-mediated ectopic expression of Ascl1 alone is sufficient for the robust reprogramming of glial cells in multiple regions of the brain (Liu et al. 2015) , raising the potential of clinical applications. Small-molecule-based methods should also be explored. Treating animals with VPA, calcitriol, or α-tocotrienol greatly facilitates the in vivo reprogramming process (Gascon et al. 2016; Niu et al. 2015 Niu et al. , 2013 Su et al. 2014a) . Cocktails of small molecules have also been shown to be sufficient for the neuronal conversion of cultured human astrocytes (Gao et al. 2017; Zhang et al. 2015) . These exciting results suggest that future research is required in order to devise clinically relevant strategies for cell fate reprogramming in vivo.
In conclusion, recent research has made great strides in neuronal reprogramming in the mammalian brain and spinal cord. The ability to create useful neurons from abundant and ubiquitously distributed glial cells raises high hopes for regenerative therapies for patients with neural injuries or degenerative conditions. A bright future lies ahead; more research is warranted.
